Recently, circulating tumor DNA (ctDNA) analysis revealed that BLU-945 achieved a median 48% reduction in EGFR resistance mutations (T790M and C797S), which represented emerging evidence of the efficacy of BLU-945 [129]. The gene discussed is EGFR; the disease is neoplasm.